Patent number: 7879838
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
Type:
Grant
Filed:
February 14, 2006
Date of Patent:
February 1, 2011
Assignees:
Schering Corporation, Pharmacopeia Drug Discovery, Inc.
Inventors:
Qingbei Zeng, De-Yi Yang, Stuart B. Rosenblum, Michael K. C. Wong, Gopinadhan N. Anilkumar, Seong Heon Kim, Wensheng Yu, Joseph A. Kozlowski, Neng-Yang Shih, Brian F. McGuinness, Lisa Guise Zawacki, Doublas W. Hobbs
Patent number: 7868005
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
Type:
Grant
Filed:
February 14, 2006
Date of Patent:
January 11, 2011
Assignee:
Schering Corporation
Inventors:
Stuart B. Rosenblum, Seong Heon Kim, Qingbei Zeng, Michael K. C. Wong, Gopinadhan N. Anilkumar, Yueheng Jiang, Wensheng Yu, Joseph A. Kozlowski, Neng-Yang Shih, Bandarpalle B. Shankar, Brian F. McGuinness, Guizhen Dong, Lisa Guise Zawacki, Douglas W. Hobbs, John J. Baldwin, Yuefei Shao
Patent number: 7566718
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
Type:
Grant
Filed:
February 14, 2006
Date of Patent:
July 28, 2009
Assignees:
Schering Corporation, Pharmacopeia Drug Discovery, Inc.
Inventors:
Michael K. C. Wong, Youheng Shu, Wensheng Yu, Stuart B. Rosenblum, Joseph A. Kozlowski, Brian F. McGuinness, Yuefei Shao, Douglas W. Hobbs